CTRI/2014/09/005000
Recruiting
Phase 4
A prospective, comparative study of the incidence and severity of constipation with darifenacin and trospium in overactive bladder.
Self Dr Manjunatha R0 sites30 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Self Dr Manjunatha R
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male and female patients aged \>\=18 and \<80 years who were diagnosed with OAB based on their overactive bladder symptoms.
- •Patients with a baseline score for urinary urgency of \>\=2 points, day time frequency \>1 point and a total OABSS of \>\=3 points, with or without urgency urinary incontinence (UUI) episodes
- •Patients with stable doses of alpha blockers or 5\-alpha\-reductase inhibitors for patients with benign prostatic hyperplasia were permitted with the limitation that a specific drug was used without a change in dosage and administration and was not replaced with another drug during the study period (observation and treatment phase).
Exclusion Criteria
- •Serious heart disease,
- •Untreated angle\-closure glaucoma,
- •Myasthenia gravis,
- •Gastric outlet and intestinal obstruction, paralytic ileus, gastric and intestinal atony or risk of urinary or gastric retention.
- •Residual urine volume \>\=100 mL (determined by abdominal sonography)
- •Strong possibility of prostate and bladder cancer
- •Acute active urinary tract infection
- •Women of childbearing age were required not to be pregnant or nursing, and to be using acceptable methods of contraception.
- •Concomitant treatments known to affect urinary bladder function like anticholinergics, antispasmodics, serotonin\-noradrenaline\-reuptake\-inhibitors, TCA, first generation antihistaminics, cholinergic agonists, cholinesterase inhibitors (e.g. bethanecol, donepezil and rivastigmine), potent inhibitors of cytochrome CYP3A4 (e.g. ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone), potent P\-glycoprotein inhibitors (e.g. cyclosporine and verapamil), aluminum antacids, antiparkinson and antipsychotic drugs, Calcium channel blockers, opioids, muscle relaxants, angiotensin\-converting enzyme inhibitors, anticoagulants.
- •Severe hepatic or renal dysfunction
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Comparative study to see the incidence of post dural puncture headache with the use of 25G Quincke and 25G Whitacre needleCTRI/2022/12/048601Dr Gayatri Karandikar
Completed
Not Applicable
Prospective study of evaluating the incidence and clinical outcomes of bioprosthetic aortic-valve thrombosisAortic stenosisJPRN-UMIN000023940Keio University School of Medicine300
Recruiting
Phase 4
Comparative study between Liposomal Amphoterisin B and Miltefosine in post kala azar dermal LeishmaniasisHealth Condition 1: null- Suffering from Post Kala Azar Dermal LeishmaniasisCTRI/2018/06/014579Department of Pharmacology
Not yet recruiting
Not Applicable
Impact of body shape criticism among college students.CTRI/2023/06/053721Manipal College of Nursing
Not yet recruiting
Phase 4
Comparison of two different spinal needle for post sugical headache in pregnant women undergoing caesarean sectioHealth Condition 1: O00-O9A- Pregnancy, childbirth and the puerperiumCTRI/2024/05/066881Pondicherry institute of medical sciences